Dr Ena Prosser is a Partner in Fountain Healthcare Partners. Ena was part of the team that raised Fountain's initial fund in 2008. Ena is a PhD biotechnologist by training and has a broad background in international alliance and intellectual property management. She has led due diligence projects on technologies and products within the specialty pharma, diagnostic, device and biotechnology areas. She led the investment in Genable Ltd (sold to Spark Therapeutics Inc in 2013) and led the Series B investment in NeRRe Therapeutics Ltd and KaNDY Therapeutics Ltd.
Ena was formerly Director of Enterprise Ireland BIO. In this role, she led a large team to identify, fund, protect and exploit relevant Intellectual Property, commercialise lifescience technologies and review investment opportunities in R&D.
Prior to Enterprise Ireland, Ena held various R&D and project management roles within Elan Corporation and had extensive involvement in drug delivery development, licensing and acquisition projects over a 9-year period. Ena has a strong innovation policy background and is a member of the Irish Government Innovation Taskforce in Intellectual Property, as well as being a council member of Knowledge Transfer Ireland. Ena works closely with leading ophthalmology research charities Foundation Fighting Blindness - Clinical Research Institute (USA) and Fighting Blindness Ireland. Ena is an Adjunct Professor at University College Dublin and a member of the Institute of Directors (Cert. Comp Dir).